Closing the Translational Gap in Inflammation and Immunology
A. Methodology
A. Methodology
Our methodology combines three core capabilities
Our methodology combines three core capabilities
Our methodology combines three core capabilities
Functional Disease Atlas at Scale
Functional Disease Atlas at Scale
We're building the world's largest functional perturbation atlas of immune disease, capturing not just cellular states but how patient cells actually respond to intervention and perturbation. Unlike genomic databases that capture only static potential, our atlas captures actual cellular behavior, the real determinant of therapeutic response.
We're building the world's largest functional perturbation atlas of immune disease, capturing not just cellular states but how patient cells actually respond to intervention and perturbation. Unlike genomic databases that capture only static potential, our atlas captures actual cellular behavior, the real determinant of therapeutic response.
Functional Disease Atlas
at Scale
We're building the world's largest functional perturbation atlas of immune disease, capturing not just cellular states but how patient cells actually respond to intervention and perturbation. Unlike genomic databases that capture only static potential, our atlas captures actual cellular behavior, the real determinant of therapeutic response.
Lab-in-the-Loop Perturbation
Lab-in-the-Loop Perturbation
We systematically test therapeutic hypotheses against live patient material using high-throughput, functional readouts. This lab-in-the-loop approach allows us to resolve individual patient variation and identify the spanning biological mechanisms that drive disease across cohorts.
We systematically test therapeutic hypotheses against live patient material using high-throughput, functional readouts. This lab-in-the-loop approach allows us to resolve individual patient variation and identify the spanning biological mechanisms that drive disease across cohorts.
Lab-in-the-Loop
Perturbation
We systematically test therapeutic hypotheses against live patient material using high-throughput, functional readouts. This lab-in-the-loop approach allows us to resolve individual patient variation and identify the spanning biological mechanisms that drive disease across cohorts.
Active Learning for Immunology
Active Learning for Immunology
By integrating AI-driven experimental design with functional patient data, we make immunology tractable at scale. Our AI learns from each experiment, continuously refining its predictions and accelerating the discovery of mechanisms that drive disease to better positioning for curative I&I programs and impact throughout the drug discovery and development value chain.
By integrating AI-driven experimental design with functional patient data, we make immunology tractable at scale. Our AI learns from each experiment, continuously refining its predictions and accelerating the discovery of mechanisms that drive disease to better positioning for curative I&I programs and impact throughout the drug discovery and development value chain.
Active Learning for
Immunolog
By integrating AI-driven experimental design with functional patient data, we make immunology tractable at scale. Our AI learns from each experiment, continuously refining its predictions and accelerating the discovery of mechanisms that drive disease to better positioning for curative I&I programs and impact throughout the drug discovery and development value chain.
B.How we work
B.How we work
B.How we work
The Challenge
Immune and inflammatory diseases affect hundreds of millions of patients worldwide, yet clinical success rates remain stubbornly low. Traditional drug discovery relies on simplified models and static snapshots that fail to capture the dynamic complexity of human immune biology. The result? High failure rates, billion-dollar losses, and patients left waiting for effective therapies.
Immune and inflammatory diseases affect hundreds of millions of patients worldwide, yet clinical success rates remain stubbornly low. Traditional drug discovery relies on simplified models and static snapshots that fail to capture the dynamic complexity of human immune biology. The result? High failure rates, billion-dollar losses, and patients left waiting for effective therapies.
Our Solution
GraphTx is pioneering a new approach to precision immunology. We front-load clinical development by identifying and validating drug targets in live patient samples, long before the clinical trial begins. Our AI-driven platform systematically captures, perturbs, and decodes patient immune biology at unprecedented scale, transforming chaotic cellular data into actionable therapeutic insights.
Our Impact
By validating biology in real human cells before significant capital deployment, we fundamentally change the risk profile of drug development. Therapies emerging from our platform enter the clinic with unprecedented biological validation, reducing failure rates, accelerating timelines, and ultimately delivering better medicines to patients faster.
C. Team
C. Team
C. Team
Environment and team are critical to innovation
We believe the most innovative teams are driven by trust and action
We believe the most innovative teams are driven by trust and action
D. Team
D. Team
D. Team
Copyright GraphTx 2026
Vienna, Asutria
Vienna, Austria
All system opperational